---
title: 64Cu-GRIP B in Patients With Advanced Malignancies
nct_id: NCT05888532
overall_status: RECRUITING
phase: PHASE1, PHASE2
sponsor: Rahul Aggarwal
study_type: INTERVENTIONAL
primary_condition: Prostate Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05888532.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05888532"
ct_last_update_post_date: 2026-03-17
last_seen_at: "2026-05-12T06:37:05.214Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# 64Cu-GRIP B in Patients With Advanced Malignancies

**Official Title:** A First-in-Human, Phase I/II PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced Malignancies

**NCT ID:** [NCT05888532](https://clinicaltrials.gov/study/NCT05888532)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 91
- **Lead Sponsor:** Rahul Aggarwal
- **Collaborators:** National Cancer Institute (NCI), U.S. Army Medical Research Acquisition Activity
- **Conditions:** Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor, Metastatic Castration-resistant Prostate Cancer, Solid Tumor, Adult
- **Start Date:** 2023-05-25
- **Completion Date:** 2027-01-31
- **CT.gov Last Update:** 2026-03-17

## Brief Summary

This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has spread to nearby tissue or lymph nodes (advanced). Granzyme B (GrB) is a biomarker produced by immune cells in response to immunotherapy, which may highlight tumors that are more likely to respond to treatment. The study population is focused on genitourinary (GU) malignancies, including renal cell and urothelial cancer, two tumor types with high mutational burden and tumor infiltrating lymphocytes compared to other tumor types, and have a predictable response rate at the population level to immune checkpoint inhibitors. The information gained from this trial may allow researchers to develop future trials where 64Cu-GRIP B PET may serve as a biomarker to monitor early response to immunomodulatory therapies which are used to stimulate or suppress the immune system and may help the body fight cancer.

## Detailed Description

PRIMARY OBJECTIVES:

I. To determine the safety, dosimetry, and pharmacokinetics of 64Cu-GRIP B PET in patients with solid tumor malignancy (3 males, 3 females). (Cohort A) II. To determine the mean percent change in both tumor maximum standardized uptake value (SUVmax) and ratio of SUVmax//blood average standardized uptake value (SUVave) on 64Cu-GRIP B PET in patients with participants with metastatic renal cell carcinoma (RCC) and urothelial carcinoma (UC) (Cohort B) or metastatic castration-resistant prostate cancer (mCRPC) (Cohort C).

SECONDARY OBJECTIVES:

I. To determine the safety and average organ dosimetry of 64Cu-GRIP B PET in patients with participants with metastatic RCC and UC (Cohort B), mCRPC (Cohort C) or other solid tumor malignancies (Cohort D).

II. To descriptively report the patterns of intra-tumoral uptake of 64Cu-GRIP B on whole body PET, including by site of disease, uptake by tumor type, inter-tumoral and inter-patient heterogeneity, and tumor-to-background signal in patients with participants with metastatic RCC and UC (Cohort B), mCRPC (Cohort C), or other solid tumor malignancies (Cohort D).

III. To descriptively report PET at grade \>= 2 immune-related adverse event(s) in patients with metastatic RCC and UC (Cohort B) who have 64Cu-GRIP B PET performed within 14 days of onset of event.

IV. To descriptively report the number of lesions identified on 64Cu-GRIP B PET compared with conventional imaging in patients with participants with metastatic RCC and UC (Cohort B), mCRPC (Cohort C), or other solid tumor malignancies (Cohort D).

V. To determine whether baseline uptake on 64Cu-GRIP B PET is associated with subsequent clinical outcomes including objective response, progression-free survival, prostate-specific antigen 50% reduction (PSA50) response, and immune-related adverse events in participants with metastatic RCC and UC (Cohort B), mCRPC (Cohort C), or other solid tumor malignancies (Cohort D).

OUTLINE: Patients are assigned to 1 of 4 cohorts:

Cohort A: Participants with metastatic GU malignancy (renal,urothelial, or prostate) Cohort B: Participants with metastatic renal cell carcinoma (RCC) or urothelial cancer (UC).

Cohort C: Participants with mCRPC Cohort D: Participants with solid tumor malignancies

All participants will receive 64Cu-GRIP B PET at baseline. For participants in Cohorts B and C, another PET scan will be performed 8 weeks and at disease progression. Participants in Cohort D will undergo PET/CT or PET/MRI throughout the study and may undergo an optional 64Cu-GRIP B PET at the time of progression. Safety monitoring includes adverse event assessment at screening, 60 minutes (+/- 15 min), 2 hours (+/- 30 min), and 24 hours (+/- 4 hours) following 64Cu-GRIP B injections. Participants will be followed for up to 2 years for longitudinal endpoints.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Disease characteristics by cohort, as defined by:

   Cohort A:
   * Histologically-confirmed metastatic solid tumor malignancy (3 Male, 3 Female)
   * Locally advanced or metastatic disease on conventional imaging

   Cohort B:
   * Histologically-confirmed metastatic renal cell carcinoma (any histologic sub-type) or urothelial carcinoma
   * Locally advanced or metastatic disease on conventional imaging

   Cohort C:
   * Histologically-confirmed prostate adenocarcinoma
   * Metastatic castration resistant prostate cancer by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria
2. Planned treatment with immune checkpoint inhibitor (Cohorts B and C only)
3. Willing to undergo paired tumor biopsies and has safely accessible bone or soft tissue lesion (Cohorts B and C only)
4. The subject is able and willing to comply with study procedures and provide signed and dated informed consent.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
6. Age 18 years or older at the time of study entry.
7. Adequate organ function, as defined by:

   * Serum creatinine \<= 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \> 60 mL/min
   * Total bilirubin \<= 1.5 x ULN (\< 3 x ULN in patients with documented or suspected Gilbert's).
   * Hemoglobin \>= 8.0 g/dL
   * Platelet count \>= 75,000/microliter
   * Absolute neutrophil count ≥ 1000/microliter
8. Patients must not be pregnant or breast feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of PET Imaging scan. Effective contraception (men and women) must be used in subjects of child-bearing potential.

Exclusion Criteria:

1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.
2. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.
3. Is currently pregnant or breastfeeding.
```

## Arms

- **Cohort A: 64Cu-GRIP B, Solid Tumor Malignancy participants** (EXPERIMENTAL) — Participants with solid tumor malignancies (3 males, 3 females), dosimetry calculation will be performed by obtaining whole body (vertex to thighs) PET images up to five time points from 0.5 to 24 hours post 64Cu-GRIP B injections. An additional intravenous line will be placed in the contra-lateral arm to collect blood for this group.
- **Cohort B: 64Cu-GRIP B, RCC and UC participants** (EXPERIMENTAL) — Participants with renal cell and urothelial carcinoma will have longitudinal imaging performed prior to treatment outside of this study with anti-programmed death-1 (PD-1)/anti-PD-1 ligand 1 (PD-L1) blockade (with or without concomitant anti-CTLA4 treatment), after 8 weeks of checkpoint blockade, and again at the time of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- **Cohort C: 64Cu-GRIP B, mCRPC participants** (EXPERIMENTAL) — Participants with metastatic castration resistant prostate cancer (mCRPC)) will have longitudinal imaging performed prior to treatment outside of this study, 8 weeks following initiation of treatment outside of this study, and at the time of disease progression by Prostate Cancer Working Group 3 (PCWG3) criteria.
- **Cohort D: 64Cu-GRIP B, Advanced malignancies** (EXPERIMENTAL) — participants with solid tumor malignancies will have longitudinal imaging performed prior to treatment outside of this study, 8 weeks following initiation of treatment, and the opportunity to have an optional scan at the time of progression.

## Interventions

- **Copper-64 labeled Granzyme B (64Cu-GRIP B)** (DRUG) — Given IV prior to imaging
- **Positron Emission Tomography (PET)** (PROCEDURE) — Imaging procedure

## Primary Outcomes

- **Frequency of treatment-emergent adverse events (Cohort A)** _(time frame: Up to 8 weeks)_ — For Cohort A, the frequency and severity of adverse events following 64Cu-GRIP B injection will be descriptively reported, using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
- **Percent of injected activity (Cohort A)** _(time frame: Up to 8 weeks)_ — For Cohort A, the tracer kinetics is measured in the organs and total-body, and the % of injected activity for each time point will be recorded for participants in Cohort A. This information is used as input for organ and whole-body effective dose calculation using Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM). This will provide the data of whole-body effective dose (millisievert (mSv)/megabecquerels (MBq)), and organ doses.
- **Time to maximum observed concentration (Tmax) (Cohort A)** _(time frame: Up to 8 weeks)_ — Pharmacokinetic (PK) parameters for participants in Cohort A derived from plasma will be calculated using a non-compartmental approach with a log-linear terminal assumption for up to a possible 5 time points. A custom software package or a commercial software package like Phoenix WinNonlin will be used to compute the time it takes for a drug to reach the maximum concentration (Cmax) after administration of a drug that needs to be absorbed.
- **Maximum observed concentration (Cmax) (Cohort A)** _(time frame: Up to 8 weeks)_ — PK parameters for participants in Cohort A derived from plasma will be calculated using a non-compartmental approach with a log-linear terminal assumption for up to a possible 5 time points. A custom software package or a commercial software package like Phoenix WinNonlin will be used to compute the maximum concentration (Cmax) after administration of a drug that needs to be absorbed.
- **Area under the concentration-time curve (AUC) (Cohort A)** _(time frame: Up to 8 weeks)_ — PK parameters for participants in Cohort A derived from plasma will be calculated using a non-compartmental approach with a log-linear terminal assumption for up to a possible 5 time points. A custom software package or a commercial software package like Phoenix WinNonlin will be used to compute the area under the concentration-time curve (AUC) from hour 0 to the last measurable concentration (AUC0-t; min\*unit/mL)
- **AUC extrapolated to infinity (Cohort A)** _(time frame: Up to 8 weeks)_ — PK parameters for participants in Cohort A derived from plasma will be calculated using a non-compartmental approach with a log-linear terminal assumption for up to a possible 5 time points. A custom software package or a commercial software package like Phoenix WinNonlin will be used to compute the AUC extrapolated to infinity (AUC0-∞; min\*unit/mL)
- **Median clearance (Cohort A)** _(time frame: Up to 8 weeks)_ — PK parameters for participants in Cohort A derived from plasma will be calculated using a non-compartmental approach with a log-linear terminal assumption for up to a possible 5 time points. A custom software package or a commercial software package like Phoenix WinNonlin will be used to compute the volume of plasma which is completely cleared of a substance per minute (mL/min).
- **Apparent terminal elimination rate constant (Cohort A)** _(time frame: Up to 8 weeks)_ — PK parameters for participants in Cohort A derived from plasma will be calculated using a non-compartmental approach with a log-linear terminal assumption for up to a possible 5 time points. A custom software package or a commercial software package like Phoenix WinNonlin will be used to compute the apparent terminal elimination rate constant.
- **Apparent terminal elimination half-life (Cohort A)** _(time frame: Up to 8 weeks)_ — PK parameters for participants in Cohort A derived from plasma will be calculated using a non-compartmental approach with a log-linear terminal assumption for up to a possible 5 time points. A custom software package or a commercial software package like Phoenix WinNonlin will be used to compute apparent terminal elimination half-life (t1/2; min).
- **Change in SUVmax (Cohorts B, C, and D)** _(time frame: Up to 8 weeks)_ — For Cohorts B, C and D, descriptive statistics will be used to summarize the change in SUVmax from baseline to 8 weeks at lesion level for participants in Cohorts B \& C.
- **Change in SUVmax/SUVave (Cohorts B, C, and D)** _(time frame: Up to 8 weeks)_ — For Cohorts B, C and D, descriptive statistics will be used to summarize the change in the ratio of SUVmax/SUVave from baseline to 8 weeks at lesion level for participants in Cohorts B \& C.

## Secondary Outcomes

- **Frequency of treatment-emergent adverse events (Cohorts B, C, and D)** _(time frame: Up to 8 weeks)_
- **Mean SUVmax in metastatic lesions by disease site (Cohorts B, C and D)** _(time frame: Up to 2 years)_
- **Percent of lesions detected for metastatic participants (Cohorts B, C and D)** _(time frame: Up to 8 weeks)_
- **Median change in SUVmax from baseline with reported immune-related adverse event (Cohort B)** _(time frame: Up to 2 years)_
- **Median change in SUVmax-ave from baseline with reported immune-related adverse event (Cohorts B)** _(time frame: Up to 2 years)_
- **Association of baseline uptake with object response (ORR) (Cohorts B, C and D)** _(time frame: Up to 2 years)_
- **Association of baseline uptake with progression-free survival (PFS) (Cohorts B, C and D)** _(time frame: Up to 2 years)_
- **Association of baseline uptake with reported PSA50 response (Cohort C)** _(time frame: Up to 2 years)_
- **Association of baseline uptake with reported immune-related adverse events (irAEs)(Cohorts B, C and D)** _(time frame: Up to 2 years)_

## Locations (1)

- University of California, San Francisco, San Francisco, California, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of california, san francisco|san francisco|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05888532.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05888532*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*